Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Assets: 2013-2024

Historic Non-Current Assets for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $16.9 million.

  • Ocular Therapeutix's Non-Current Assets rose 37.70% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 37.70%. This contributed to the annual value of $16.9 million for FY2024, which is 14.51% down from last year.
  • Per Ocular Therapeutix's latest filing, its Non-Current Assets stood at $16.9 million for FY2024, which was down 14.51% from $19.8 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Non-Current Assets peaked at $19.8 million during FY2023, and registered a low of $13.6 million during FY2021.
  • Over the past 3 years, Ocular Therapeutix's median Non-Current Assets value was $19.7 million (recorded in 2022), while the average stood at $18.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first declined by 15.44% in 2020, then surged by 44.71% in 2022.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Non-Current Assets stood at $15.7 million in 2020, then fell by 13.48% to $13.6 million in 2021, then spiked by 44.71% to $19.7 million in 2022, then rose by 0.83% to $19.8 million in 2023, then declined by 14.51% to $16.9 million in 2024.